Sage Journals: Discover world-class research

Open access

Research article

First published 2025

Switch from fingolimod to ozanimod for safety or intolerance reasons

Elisabetta Signoriello, Giuseppe Romano, Matteo Foschi [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Review article

First published 2022-5

Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

David Choi, Alyssa P. Stewart, Shubha Bhat

Annals of Pharmacotherapy

Open access

Research article

First published 2024

Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons

Damemarie Paul, Elyse Swallow, Oscar Patterson-Lomba [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2025-11

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2019-8

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Jeffrey A Cohen, Giancarlo Comi, Douglas L Arnold [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022-10

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce AC Cree, Krzysztof W Selmaj, Lawrence Steinman [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2024-2

Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial

Robert T Naismith, Jeffrey A Cohen, Amit Bar-Or [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2025-9

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

Jeffrey A Cohen, Douglas L Arnold, John DeLuca [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2024

Appropriateness of small molecule agents for patients with IBD of childbearing age – a RAND/UCLA appropriateness panel

Christian Selinger, Robyn Laube, Jimmy K. Limdi [...]

Therapeutic Advances in Gastroenterology

Free access

Review article

First published 2017-10

Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges

Marcel Vetter, Markus F. Neurath

Therapeutic Advances in Gastroenterology

Search results